The Union Health Budget 2026 has unveiled a push to the healthcare sector that will make the country self-reliant and globally credible in the long term. "The Union Budget 2026-27 lays a strong foundation for positioning India as a global hub for life sciences innovation and advanced biopharma manufacturing. The Rs 10,000 crore outlay under the Biopharma Shakti initiative, coupled with the expansion and upgradation of NIPERs, will significantly strengthen India`s research, talent and innovation ecosystem in high-value biologics and advanced therapeutics.

Measures to enhance CDSCO capabilities and streamline clinical trial compliances are particularly encouraging, as they will improve regulatory efficiency and global credibility. The integrated focus on innovation and manufacturing scale-up will accelerate innovation-led pipelines and enable deeper global collaborations," said Mayank Singhal, Vice Chairperson & Managing Director, PI Industries.